Truist Financial Corp increased its holdings in GSK plc (NYSE:GSK – Free Report) by 3.5% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 228,470 shares of the pharmaceutical company’s stock after purchasing an additional 7,778 shares during the quarter. Truist Financial Corp’s holdings in GSK were worth $8,129,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors also recently added to or reduced their stakes in the company. Centerpoint Advisors LLC raised its position in GSK by 115.8% in the 1st quarter. Centerpoint Advisors LLC now owns 846 shares of the pharmaceutical company’s stock worth $30,000 after purchasing an additional 454 shares during the period. Glassman Wealth Services grew its holdings in GSK by 504.6% in the 4th quarter. Glassman Wealth Services now owns 925 shares of the pharmaceutical company’s stock worth $33,000 after acquiring an additional 772 shares during the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC grew its holdings in GSK by 61.3% in the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 968 shares of the pharmaceutical company’s stock worth $42,000 after acquiring an additional 368 shares during the last quarter. Concord Wealth Partners bought a new stake in GSK in the 4th quarter worth $45,000. Finally, Cowa LLC bought a new stake in GSK in the 1st quarter worth $45,000. Hedge funds and other institutional investors own 13.29% of the company’s stock.
GSK Trading Down 0.3 %
Shares of GSK opened at $35.08 on Friday. GSK plc has a 1-year low of $28.47 and a 1-year high of $39.74. The company has a current ratio of 0.88, a quick ratio of 0.63 and a debt-to-equity ratio of 1.28. The firm’s 50-day moving average price is $34.95 and its 200-day moving average price is $35.37. The firm has a market capitalization of $71.83 billion, a price-to-earnings ratio of 4.02, a PEG ratio of 1.72 and a beta of 0.67.
GSK Cuts Dividend
Analyst Upgrades and Downgrades
A number of equities research analysts have issued reports on GSK shares. StockNews.com lowered shares of GSK from a “strong-buy” rating to a “buy” rating in a report on Tuesday. HSBC began coverage on shares of GSK in a research note on Friday, July 14th. They set a “reduce” rating on the stock. Four analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, GSK presently has a consensus rating of “Hold” and an average price target of $1,527.50.
View Our Latest Analysis on GSK
GSK Company Profile
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Read More
- Five stocks we like better than GSK
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Alibaba Explodes On Earnings, Inching Toward Triple Digit Prices
- How to Invest in EV Charging Stations
- Is It Time To Game The Roblox Market?
- EV Stocks and How to Profit from Them
- 2 Cheap Stocks The Insiders Are Buying
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSK – Free Report).
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
